Abstract: Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse in a hair wash sample are provided. The compositions include two or more analytes associated with a solid phase, e.g., a particle or a multiwell plate. The compositions and methods also allow the simultaneous, tandem, or serial determination of the presence and/or amount of two or more analytes of interest in a hair wash sample.

Abstract: The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.

Abstract: Provided is a protein quantitation standard having polypeptides of different molecular weights that functions as a mass quantitation standard in one lane of an electrophoretic gel. The protein quantitation standard includes unstained polypeptides having different electrophoretic mobilities that are present in different quantities, such that the bands in the gel have different intensities when visualized. The protein quantitation standard can also contain prestained polypeptides that function as visual molecular weight markers. Also provided are methods of determining the mass of a target polypeptide or protein using the protein quantitation standard.

Abstract: The present invention provides, inter alia, transgenic non-human animals, such as transgenic mice. The animals contain in their genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide, which polypeptide forms a thrombus when in the presence of human platelets. Nucleic acid sequences and vectors for generating the transgenic non-human animals, and methods for using the transgenic non-human animals are provided as well. Chimeric VWF proteins are also provided.

Abstract: Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer.

Abstract: The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of selecting affinity molecules such as natural antibodies, including artificial antibodies, antibody mimics, and aptamers. The invention relates particularly to a method of selecting affinity molecules using a homogeneous noncompetitive assay in a high throughput process.

Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.

Abstract: A method of diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject, which includes the step of i) determining the platelets' myosin non-muscle heavy chain 10 (MYH10) expression level in a biological sample from the subject, and wherein a detectable platelets' MYH10 expression level is indicative of a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation, and to a kit for diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject including i) at least one antibody for determining the platelet MYH10 expression level in a biological sample from the subject, which can be used in a such a method.

Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract: Disclosed herein is a method for the detection or preliminary screening of coronary artery disease, including: obtaining a urine sample from a human subject suspected of having coronary artery disease; detecting a level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease; and comparing the detected level of sCD14 in the urine sample with a predetermined standard, wherein the level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease greater than the predetermined standard is indicative of the presence of coronary artery disease.

Abstract: The present invention relates to methods of visualizing targets in histological samples, e.g. biopsy samples, wherein the methods comprise staining of the sample with (i) one or more target specific immunochemical stains, and (ii) a histological stain for specific tissue components e.g. iron, mucins glycogen, amyloid, nucleic acids, etc., e.g. hematoxilyn and/or eosin stains or the like, that is used to enhance contrast in the microscopic image of a tissue sample, highlight morphologic structures in the sample for viewing, define and examine tissues, cell populations, or organelles within individual cells. Methods may further comprise evaluation of expression of one or more targets in the sample. The disclosed methods are useful for medical diagnostics.

Abstract: A method is provided for detecting a target molecule in a biological sample. One step of the method includes immobilizing the biological sample on a membrane. Next, the membrane-bound biological sample is contacted with at least one detection moiety. The membrane-bound biological sample is then separately mated with a substrate and the target molecule detected. At least one step of the method is performed under positive pressure or a vacuum.

Abstract: We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.

Abstract: The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the MIP is a nanoparticle (a molecularly imprinted polymeric nanoparticle (MIPNP)). Other aspects of the invention include methods of preparing an MIP having affinity for a natriuretic peptide, methods for binding a natriuretic peptide in vitro or in vivo using an MIP of the invention, methods for interfering with the binding of a natriuretic peptide with its receptor in vivo, methods for reducing inflammation, cell growth, cell differentiation, or a cell proliferation disorder, methods for detecting natriuretic peptides, and devices and kits for sequestering and/or detecting natriuretic peptides.

Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.

Abstract: The application relates to methods and systems for analysis of dissociation behavior of nucleic acids and identification of nucleic acids. In one aspect, methods and systems are disclosed for identifying a nucleic acid in a sample including an unknown nucleic acid and for detecting a single nucleotide polymorphism in a nucleic acid in a sample. Methods and systems are also disclosed for identification of a nucleic acid in a biological sample including at least one unknown nucleic acid by fitting denaturation data including measurements of a quantifiable physical change of the sample at a plurality of independent sample property points to a function to determine an intrinsic physical value and to obtain an estimated physical change function, and identifying the nucleic acid in the biological sample by comparing the intrinsic physical value for at least one unknown nucleic acid to an intrinsic physical value for a known nucleic acid.

Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.

Abstract: In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the Bcl-2 family of proteins. It is named BLID (Bcl2 family of proteins Like Interaction Domain). Use of BLID and its variants for modulating cellular activity is presented. BLID, its variants and or anti-BLID antibodies could be useful as a screening tool as well as for discovery of drugs that help fight pathological states like degenerative diseases, cerebral or cardiac ischemic hypoxic disorders, cancer and autoimmunity.

Abstract: The present invention provides methods of detecting cancer using biomarkers.

Abstract: Use of autophagic activity in regulation of the amount of melanin in a keratinocyte, the control of skin or hair color, or selection of an agent for regulating the amount of melanin in a keratinocyte or an agent for controlling skin or hair color.

Abstract: A method of differentiating oncogenic changes of the thyroid encompassing follicular adenoma and follicular cancer, characterised in that in a sample of oncogenic tissue from a patient the expression of the metallothionein (MT) potein is evaluated using immunochistochemical methods using monoclonal anti-MT antibodies, the degree of intensity of the expression of metallothionein is evaluated under a light microscope using the semiquantitative IRS method according to Remmele, wherein if the degree of intensity of the expression of metallothionein is equal to or greater than 8 on the semiquantitative IRS scale then the presence of follicular cancer is indicated.

Abstract: The object of the present invention is to provide: a test kit for an antibody titer or an antibody against a periodontal disease-causing bacterium in a blood sample, which enables the testing on a periodontal disease in patients having a wide scope of immunotypes with high accuracy and can be treated by an automated device at a high speed; a periodontal disease-causing bacterium antigen protein which can be suitably used in the kit; a method for testing an antibody titer or the presence of an antibody in a blood sample using the kit; and a kit for typing strains of Porphyromonas gingivalis.

Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.

Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).

Abstract: The present invention relates to methods of diagnosing hypophosphatemic disorders.

Abstract: Methods are provided for detection of a target cell type within a cell population, and compositions are provided comprising cells and an indicator that indicates the number of cells of the target cell type in the cell population. Examples are provided in which these methods are used to detect human embryonic stem cells within a differentiated cell population with exquisite sensitivity. Differentiated cells produced from embryonic stem cells can be characterized by these methods before transplantation into a recipient, thereby providing further assurance of safety.

Abstract: A novel biomarker for diagnosing amyloid ?-related neuropathy such as Alzheimer's disease is provided. Disclosed is a method for diagnosing Alzheimer's disease comprising measuring the level of a MFG-E8 protein in a blood, serum or plasma sample obtained from a human or animal subject, wherein the measured value is used as a marker for diagnosis of Alzheimer's disease. The MFG-E8 protein is found to bind to phosphatidylserine in a Ca2+ dependent manner in a culture supernatant of mouse brain nerve cells, which are a dementia model stimulated with A?42. It is also found that the level of the MFG-E8 protein is increased in patients with Alzheimer's disease.

Abstract: A method of analyzing exosomes, the method comprising incubating a sample comprising fluorescence-labeled exosomes with a solid support so that the fluorescence-labeled exosomes bind to the solid support; measuring a fluorescence signal from the bound fluorescence-labeled exosomes; and analyzing the exosomes based on the measured fluorescence signal.

Abstract: The invention provides, in certain embodiments, a method of preventing and/or treating peritoneal injury and/or diminished function by administering an effective amount of one or more inhibitors of JAK. The invention also provides a pharmaceutical composition including a JAK inhibitor for the treatment of peritoneal injury and/or diminished function. In another aspect, the invention provides a method of detecting an indicator of peritoneal injury. The method entails assaying a biological sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of peritoneal injury. Also provided, are methods of identifying subject for treatment of peritoneal injury and/or diminished function, methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.

Abstract: The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

Abstract: Kits, methods of treating, and methods of diagnosing a risk level for an incisional hernia in a subject undergoing abdominal surgery are disclosed. They are designed to determine risk factors for incisional hernia formation based on a subject's unique gene expression profiles.

Abstract: Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice.

Abstract: Provided is a method of determining a therapeutic effect of cancer chemotherapy with an anticancer drug obtained by blending three ingredients, i.e., tegafur, gimeracil, and oteracil potassium as active ingredients (hereinafter abbreviated as S-1) quickly, simply, and accurately before carrying out the cancer chemotherapy. Specifically, provided is a method of determining an administration effect in chemotherapy with S-1, the method comprising: a step (a) of measuring expression level of a decorin gene in a biological sample collected from a subject to be diagnosed; and a step (b) of determining an administration effect of S-1 based on the expression level of the gene obtained from the measurement.

Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.

Abstract: The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.

Abstract: Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.

Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for treating cancers as well as determining prognosis and predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies.

Abstract: A capillary for an immunoassay is provided which comprises an insoluble layer of an oxidase formed on an inner wall surface of said capillary, said oxidase being conjugated to a first antibody, and a layer of a hydrophilic polymer formed on said insoluble layer, said hydrophilic polymer layer containing a second antibody conjugated to a peroxidase, wherein said first and second antibodies are capable of binding to the same antigen.

Abstract: Apparatus for detecting the presence of foreign substances in a beverage. The apparatus for detecting the presence of Gamma-hydroxybutyrate or other drugs in a beverage comprises apparatus wherein cobalt nitrate, oxammonium chloride/ferric chloride, oxammonium sulphate/ferric chloride, 5% ferric chloride, saturated potassium dichromate, toluene/cobalt thiocyanate, chromium (IV) oxide/sulphuric acid carbodiimide salts in combination with oxammonium salts and ferric chloride, or lacmoid is supported on a substrate. The apparatus for detecting the presence of ketamines or other drugs in a beverage comprises apparatus wherein modified-Dragendorff Reagent is supported on a substrate.

Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.

Abstract: The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.

Abstract: It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and ovarian cancers. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to the GT198 gene mutations. Another embodiment provides methods and compositions for detecting cancer due to the mutation of the GT198 gene. Still another embodiment provides methods for identifying compounds, antibodies and natural product molecules that are useful for treating cancer due to the mutations of the GT198 gene. Preferably the disclosed compositions antagonize or interfere with the biological activity of splice variants of GT198.

Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

Abstract: Assay cassettes and testing devices that can be used to provide rapid, accurate, affordable, laboratory-quality testing at the point of care. Such assay cassettes and testing devices are designed to provide rapid, quantitative test results in a point-of-care setting or the like. Likewise, such assay cassettes and testing devices may eliminate or replace expensive, centralized clinical testing equipment and technical personnel. Such testing device may include automated data reporting and decision support. Methods for performing point of care diagnostic tests are also disclosed.

Abstract: A rapid, efficient and convenient method to detect one or more biological entities on a blotting membrane is provided. The detection can relate to the position, nature or amount of the biological substance on one or more membranes. The invention method involves a pressure assisted regiment (such as vacuum or positive gas pressure) for the supply and removal of reagents and permits washing of the contaminants from substances embedded in the membrane to be detected using very low volumes of liquid. This method enables completion of the blocking, washing and antibody binding steps in about 30 minutes without comprising blot quality. In another aspect, the invention is directed to an apparatus useful in conducting the method of the invention.

Abstract: The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention.

Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.

Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.

Abstract: Disclosed herein are embodiments of a signaling conjugate, embodiments of a method of using the signaling conjugates, and embodiments of a kit comprising the signaling conjugate. The disclosed signaling conjugate comprises a latent reactive moiety and a chromogenic moiety that may further comprise a linker suitable for coupling the latent reactive moiety to the chromogenic moiety. The signaling conjugate may be used to detect one or more targets in a biological sample and are capable of being covalently deposited directly on or proximally to the target. Particular disclosed embodiments of the method of using the signaling conjugate comprise multiplexing methods.